Advertisement

Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders

      Introduction

      Hepatitis C virus testing is recommended for people at high risk for infection, including those with substance use disorders. Little is known about the cascade of hepatitis C virus care (including testing, diagnosis, and treatments) among patients with substance use disorders in real-world clinical practice. This study aims to characterize the hepatitis C virus cascade of care and identify the factors associated with hepatitis C virus testing and diagnosis among Florida Medicaid beneficiaries with substance use disorders.

      Methods

      A retrospective cohort analysis of Florida Medicaid data (2013–2018) was conducted in 2020 for patients aged 18–64 years with newly diagnosed substance use disorders (year 2012 was used to ascertain 1-year previous enrollment). A generalized estimating equation identified the factors associated with hepatitis C virus testing; a multivariable logistic model identified the factors associated with hepatitis C virus diagnosis.

      Results

      Of the 156,770 patients with substance use disorders, 18% were tested for hepatitis C virus at least once. Among the tested patients, 8% had hepatitis C virus diagnoses. Among the 2,177 patients having a hepatitis C virus diagnosis, 11% initiated hepatitis C virus treatments, and 96% of them completed the hepatitis C virus treatments. Factors associated with being less likely to receive hepatitis C virus testing included being male (AOR=0.73, 95% CI=0.71, 0.75) and White (AOR=0.85, 95% CI=0.83, 0.87), whereas individuals who were male (AOR=1.49, 95% CI=1.35, 1.66) and White (AOR=2.71, 95% CI=2.38, 3.08) were more likely to be diagnosed with hepatitis C virus. The odds of receiving hepatitis C virus testing significantly increased annually (AOR=1.06, 95% CI=1.05, 1.07).

      Conclusions

      Future studies are warranted to investigate the barriers to access hepatitis C virus testing and treatment among Florida Medicaid beneficiaries with substance use disorders, especially for White male individuals.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Frimpong JA
        • D'Aunno T
        Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services.
        Subst Abuse Treat Prev Policy. 2016; 11: 13https://doi.org/10.1186/s13011-016-0057-2
        • Rodriguez CV
        • Rubenstein KB
        • Linas B
        • Hu H
        • Horberg M.
        Increasing hepatitis C screening in a large integrated health system: science and policy in concert.
        Am J Manag Care. 2018; 24: e134-e140
        • Owens DK
        • Davidson KW
        • Krist AH
        • et al.
        • US Preventive Services Task Force
        Screening for hepatitis C virus infection in adolescents and adults: U.S. Preventive Services Task Force recommendation statement.
        JAMA. 2020; 323: 970-975https://doi.org/10.1001/jama.2020.1123
      1. Recommendations for hepatitis C screening. Hepatitis C Online.
        November 9, 2020
        • Schillie S
        • Wester C
        • Osborne M
        • Wesolowski L
        • Ryerson AB.
        CDC recommendations for hepatitis C screening among adults - United States, 2020.
        MMWR Recomm Rep. 2020; 69: 1-17https://doi.org/10.15585/mmwr.rr6902a1
        • Scholl L
        • Seth P
        • Kariisa M
        • Wilson N
        • Baldwin G.
        Drug and opioid-involved overdose deaths—United States, 2013–2017.
        MMWR Morb Mortal Wkly Rep. 2018; 67: 1419-1427https://doi.org/10.15585/mmwr.mm675152e1
        • Support to address the infectious disease consequences of the opioid crisis
        Centers for Disease Control and Prevention.
        October 11, 2019
        https://www.cdc.gov/pwid/ido.html
        Date accessed: February 20, 2021
        • Campbell JV
        • Hagan H
        • Latka MH
        • et al.
        High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three U.S. cities.
        Drug Alcohol Depend. 2006; 81: 259-265https://doi.org/10.1016/j.drugalcdep.2005.07.005
        • Russell M
        • Pauly MP
        • Moore CD
        • et al.
        The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan.
        Hepatology. 2012; 56: 1223-1230https://doi.org/10.1002/hep.25755
        • Ti L
        • Parent S
        • Socías ME.
        Integrated models of care for people living with hepatitis C virus and a substance use disorder: protocol for a systematic review.
        JMIR Res Protoc. 2018; 7: e122https://doi.org/10.2196/resprot.9532
        • Fill MA
        • Sizemore LA
        • Rickles M
        • et al.
        Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population.
        Epidemiol Infect. 2018; 146: 508-514https://doi.org/10.1017/S0950268818000080
        • Schaefer M
        • Mauss S.
        Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
        Curr Drug Abuse Rev. 2008; 1: 177-187https://doi.org/10.2174/1874473710801020177
        • Fuster D
        • Sanvisens A
        • Bolao F
        • Rivas I
        • Tor J
        • Muga R.
        Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections.
        World J Hepatol. 2016; 8: 1295-1308https://doi.org/10.4254/wjh.v8.i31.1295
        • McLellan AT.
        Substance misuse and substance use disorders: why do they matter in healthcare?.
        Trans Am Clin Climatol Assoc. 2017; 128: 112-130
      2. National opioid epidemic: drug-related deaths. Opioid & Health Indicators Database. https://opioid.amfar.org/indicator/drugdeaths. Updated December 2018. Accessed February 20, 2021.

      3. Florida Health Government. Section 1: data summaries for common reportablediseases/conditions. Tallahassee, FL: Florida Health Government. http://www.floridahealth.gov/diseases-and-conditions/disease-reporting-and-management/disease-reporting-and-surveillance/data-and-publications/_documents/2017-amr-section-1-data-summaries-for-common-reportable-diseases-and-conditions.pdf. Published December 2017. Accessed February 20, 2021.

        • Rosenberg ES
        • Rosenthal EM
        • Hall EW
        • et al.
        Prevalence of hepatitis C virus infection in U.S. states and the District of Columbia, 2013 to 2016.
        JAMA Netw Open. 2018; 1e186371https://doi.org/10.1001/jamanetworkopen.2018.6371
        • Liang TJ
        • Ward JW.
        Hepatitis C in injection-drug users—a hidden danger of the opioid epidemic.
        N Engl J Med. 2018; 378: 1169-1171https://doi.org/10.1056/NEJMp1716871
        • Holmes JA
        • Rutledge SM
        • Chung RT.
        Direct-acting antiviral treatment for hepatitis C.
        Lancet. 2019; 393: 1392-1394https://doi.org/10.1016/S0140-6736(18)32326-2
        • Christensen S
        • Buggisch P
        • Mauss S
        • et al.
        Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice?.
        Addiction. 2018; 113: 868-882https://doi.org/10.1111/add.14128
        • Ottman AA
        • Townsend ML
        • Hashem MG
        • Britt RB.
        Impact of substance use disorder on the rate of sustained virological response in veterans with chronic hepatitis C treated with direct-acting antivirals.
        Ann Pharmacother. 2019; 53: 581-587https://doi.org/10.1177/1060028018824988
        • Belli LS
        • Perricone G
        • Adam R
        • et al.
        Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
        J Hepatol. 2018; 69: 810-817https://doi.org/10.1016/j.jhep.2018.06.010
        • Backus LI
        • Belperio PS
        • Shahoumian TA
        • Mole LA.
        Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease.
        Hepatology. 2018; 68: 827-838https://doi.org/10.1002/hep.29811
        • Wang W
        • Lo Re 3rd, V
        • Guo Y
        • Xiao H
        • Brown J
        • Park H.
        Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the U.S.
        Aliment Pharmacol Ther. 2020; 52: 1592-1602https://doi.org/10.1111/apt.16081
        • Park H
        • Wang W
        • Henry L
        • Nelson DR.
        Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis C in the United States.
        Hepatology. 2019; 69: 1032-1045https://doi.org/10.1002/hep.30303
        • Younossi Z
        • Park H
        • Henry L
        • Adeyemi A
        • Stepanova M.
        Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden.
        Gastroenterology. 2016; 150: 1599-1608https://doi.org/10.1053/j.gastro.2016.02.039
        • Park H
        • Jiang X
        • Song HJ
        • et al.
        The impact of direct-acting antiviral therapy on end stage liver disease among individuals with chronic hepatitis C and substance use disorders.
        Hepatology. February 5, 2021; (In press. Online)https://doi.org/10.1002/hep.31732
        • Hajarizadeh B
        • Cunningham EB
        • Valerio H
        • et al.
        Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis.
        J Hepatol. 2020; 72: 643-657https://doi.org/10.1016/j.jhep.2019.11.012
        • Cunningham EB
        • Hajarizadeh B
        • Amin J
        • et al.
        Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people who inject drugs.
        Clin Infect Dis. 2021; 72: 1392-1400https://doi.org/10.1093/cid/ciaa253
        • Artenie AA
        • Cunningham EB
        • Dore GJ
        • et al.
        Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: an international study.
        Clin Infect Dis. 2020; 70: 2369-2376https://doi.org/10.1093/cid/ciz633
        • WHO
        Global health sector strategy on viral hepatitis 2016-2021.
        WHO, Geneva, SwitzerlandJune 2016
        • Durham DP
        • Skrip LA
        • Bruce RD
        • et al.
        The impact of enhanced screening and treatment on hepatitis C in the United States.
        Clin Infect Dis. 2016; 62: 298-304https://doi.org/10.1093/cid/civ894
        • Zur J
        • Tolbert J.
        The opioid epidemic and Medicaid’s role in facilitating access to treatment.
        Kaiser Family Foundation, San Francisco, CAMay 24, 2019
        • Kaiser Family Foundation
        Medicaid’s role in addressing the opioid epidemic.
        Kaiser Family Foundation, San Francisco, CAJune 3, 2019
        • Janjua NZ
        • Islam N
        • Kuo M
        • et al.
        Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets.
        Int J Drug Policy. 2018; 55: 31-39https://doi.org/10.1016/j.drugpo.2018.02.001
        • Lo-Ciganic WH
        • Gellad WF
        • Gordon AJ
        • et al.
        Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.
        Addiction. 2016; 111: 892-902https://doi.org/10.1111/add.13270
      4. Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Focus (Am Psychiatr Publ). 2019;17(2):158−162. https://doi.org/10.1176/appi.focus.17205.

        • Testing recommendations for hepatitis C virus infection
        Centers for Disease Control and Prevention.
        July 29, 2020
        • Isenhour CJ
        • Hariri SH
        • Hales CM
        • Vellozzi CJ.
        Hepatitis C antibody testing in a commercially insured population, 2005-2014.
        Am J Prev Med. 2017; 52: 625-631https://doi.org/10.1016/j.amepre.2016.12.016
        • Shatin D
        • Schech SD
        • Patel K
        • McHutchison JG.
        Population-based hepatitis C surveillance and treatment in a national managed care organization.
        Am J Manag Care. 2004; 10: 250-256
        • Flanigan CA
        • Leung SJ
        • Rowe KA
        • et al.
        Evaluation of the impact of mandating health care providers to offer hepatitis C virus screening to all persons born during 1945-1965 – New York, 2014.
        MMWR Morb Mortal Wkly Rep. 2017; 66: 1023-1026https://doi.org/10.15585/mmwr.mm6638a3
      5. Barocas JA, Wang J, White LF, et al. Hepatitis C testing increased among baby boomers following the 2012 change to CDC testing recommendations. Health Aff (Millwood). 2017;36(12):2142−2150. https://doi.org/10.1377/hlthaff.2017.0684.

        • Niu B
        • Forde KA
        • Goldberg DS.
        Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data.
        Pharmacoepidemiol Drug Saf. 2015; 24: 107-111https://doi.org/10.1002/pds.3721
        • Management of acute HCV infection
        American Association for the Study of Liver Diseases, Infectious Diseases Society of American.
        November 5, 2019
        • Park H
        • Song HJ
        • Jiang X
        • Henry L
        • Cook RL
        • Nelson DR.
        Direct-acting antiviral treatment use remains low among Florida Medicaid beneficiaries with chronic hepatitis C.
        Hepatol Commun. 2021; 5: 203-216https://doi.org/10.1002/hep4.1634
      6. HCV guidance: recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Diseases, Infectious Diseases Society of American. https://www.hcvguidelines.org/. Updated August 2020. Accessed May 14, 2021.

        • Bull-Otterson L
        • Huang YA
        • Zhu W
        • King H
        • Edlin BR
        • Hoover KW.
        Human immunodeficiency virus and hepatitis C virus infection testing among commercially insured persons who inject drugs, United States, 2010-2017.
        J Infect Dis. 2020; 222: 940-947https://doi.org/10.1093/infdis/jiaa017
        • Hardin JW.
        Generalized estimating equations (GEE).
        in: Everitt BS Howell DC Encyclopedia of Statistics in Behavioral Science. John Wiley & Sons, Hoboken, NJ2005https://doi.org/10.1002/0470013192.bsa250
        • O'brien RM
        A caution regarding rules of thumb for variance inflation factors.
        Qual Quant. 2007; 41: 673-690https://doi.org/10.1007/s11135-006-9018-6
      7. When and in whom to initiate HCV therapy.
        American Association for the Study of Liver Diseases, Infectious Diseases Society of American, November 6, 2019
        https://www.hcvguidelines.org/evaluate/when-whom
        Date accessed: February 20, 2021
      8. Surveillance for viral hepatitis – United States, 2016.
        Centers for Disease Control and Prevention, April 16, 2018
        • Assoumou SA
        • Wang J
        • Nolen S
        • et al.
        HCV testing and treatment in a national sample of U.S. federally qualified health centers during the opioid epidemic.
        J Gen Intern Med. 2020; 35: 1477-1483https://doi.org/10.1007/s11606-020-05701-9
        • Center for Drug Use and HIV Research
        Syringe service programs reduce HIV and HCV infections in people who inject drugs.
        Center for Drug Use and HIV Research, New York, NYMay 2017
        • Hagan H
        • McGough JP
        • Thiede H
        • Hopkins S
        • Duchin J
        • Alexander ER.
        Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors.
        J Subst Abuse Treat. 2000; 19: 247-252https://doi.org/10.1016/s0740-5472(00)00104-5
        • Hagan H
        • Pouget ER
        • Des Jarlais DC.
        A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.
        J Infect Dis. 2011; 204: 74-83https://doi.org/10.1093/infdis/jir196
        • Turner KM
        • Hutchinson S
        • Vickerman P
        • et al.
        The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
        Addiction. 2011; 106: 1978-1988https://doi.org/10.1111/j.1360-0443.2011.03515.x
        • Feldman EB
        • Balise R
        • Schiff E
        • Whitehead N
        • Thomas E.
        Barriers to hepatitis C screening in a minority population: a comparison of hepatitis C and human immunodeficiency virus screening rates at a community STD clinic in Miami, Florida.
        J Community Health. 2017; 42: 921-925https://doi.org/10.1007/s10900-017-0335-6
        • Yartel AK
        • Morgan RL
        • Rein DB
        • et al.
        HIV infection status as a predictor of hepatitis C virus RNA testing in primary care.
        Am J Prev Med. 2015; 49: 423-427https://doi.org/10.1016/j.amepre.2015.03.003
        • Kanwal F
        • Schnitzler MS
        • Bacon BR
        • Hoang T
        • Buchanan PM
        • Asch SM.
        Quality of care in patients with chronic hepatitis C virus infection: a cohort study.
        Ann Intern Med. 2010; 153: 231-239https://doi.org/10.7326/0003-4819-153-4-201008170-00005
        • Martin SA
        • Bosse J
        • Wilson A
        • Losikoff P
        • Chiodo L.
        Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care.
        Addict Sci Clin Pract. 2018; 13: 10https://doi.org/10.1186/s13722-018-0111-7
        • Serota DP
        • Barocas JA
        • Springer SA.
        Infectious complications of addiction: a call for a new subspecialty within infectious diseases.
        Clin Infect Dis. 2020; 70: 968-972https://doi.org/10.1093/cid/ciz804
        • Norton BL
        • Beitin A
        • Glenn M
        • DeLuca J
        • Litwin AH
        • Cunningham CO.
        Retention in buprenorphine treatment is associated with improved HCV care outcomes.
        J Subst Abuse Treat. 2017; 75: 38-42https://doi.org/10.1016/j.jsat.2017.01.015
        • Linas BP.
        Time for a new approach to guidance for human immunodeficiency virus and hepatitis C virus testing among persons who inject drugs.
        J Infect Dis. 2020; 222: 885-887https://doi.org/10.1093/infdis/jiaa015
        • Ho SB
        • Bräu N
        • Cheung R
        • et al.
        Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse.
        Clin Gastroenterol Hepatol. 2015; 13 (e143): 2005-2014https://doi.org/10.1016/j.cgh.2015.02.022
        • Ho SB
        • Dollarhide A
        • Thorisdottir H
        • et al.
        A primary care-based collaborative hepatitis C clinic: clinical structure and virologic outcomes with direct acting antiviral therapy.
        Open Med J. 2016; 3 (1): 70-78https://doi.org/10.2174/1874220301603010070
        • Grebely J
        • Bruneau J
        • Bruggmann P
        • et al.
        Elimination of hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy.
        Int J Drug Policy. 2017; 47: 26-33https://doi.org/10.1016/j.drugpo.2017.08.001
      9. Percent of drug treatment paid by Medicaid. Opioid & Health Indicators Database.https://opioid.amfar.org/indicator/pct_tx_med. Accessed February 20, 2021.

        • Ifeachor AP
        • Houck KK
        • Schulte S
        • et al.
        HCV eradication in veterans with underlying mental health disorders and substance use.
        J Am Pharm Assoc (2003). 2020; 60 (e3): 1037-1043https://doi.org/10.1016/j.japh.2020.08.028
        • Kim HN
        • Nance RM
        • Williams-Nguyen JS
        • et al.
        Effectiveness of direct-acting antiviral therapy in patients with human immunodeficiency virus–hepatitis C virus coinfection in routine clinical care: a multicenter study.
        Open Forum Infect Dis. 2019; 6 (ofz100)https://doi.org/10.1093/ofid/ofz100
        • Norris L.
        Florida and the ACA’s Medicaid expansion.
        healthinsurance.org, St. Louis Park, MNSeptember 8, 2020